SINTX Technologies reported third-quarter revenue of approximately $2.2 million, a tenfold increase from the prior-year period's $208,000. Gross profit rose to $1.4 million with margins expanding to 62%, while operating expenses decreased 13% to $3.0 million. The net loss narrowed by 55% to $1.6 million. Additionally, the company received approximately $2.0 million in gross proceeds from the exercise of Class B warrants at $2.14 per share following a post-quarter-end call triggered by hitting the revenue milestone. SINTX Technologies develops and commercializes silicon nitride ceramic biomaterials for medical and industrial applications.
